Allianz Asset Management GmbH Has $29.74 Million Stake in Insulet Co. (NASDAQ:PODD)

Allianz Asset Management GmbH lifted its stake in Insulet Co. (NASDAQ:PODD) by 27.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 113,921 shares of the medical instruments supplier’s stock after acquiring an additional 24,734 shares during the period. Allianz Asset Management GmbH owned 0.16% of Insulet worth $29,741,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. ING Groep NV acquired a new stake in shares of Insulet in the fourth quarter worth $556,000. Handelsbanken Fonder AB raised its holdings in Insulet by 9.9% in the 4th quarter. Handelsbanken Fonder AB now owns 18,916 shares of the medical instruments supplier’s stock worth $4,938,000 after acquiring an additional 1,700 shares during the period. Private Advisor Group LLC lifted its position in Insulet by 30.5% during the 4th quarter. Private Advisor Group LLC now owns 9,642 shares of the medical instruments supplier’s stock worth $2,517,000 after acquiring an additional 2,255 shares during the last quarter. Alberta Investment Management Corp boosted its holdings in Insulet by 57.6% during the fourth quarter. Alberta Investment Management Corp now owns 3,400 shares of the medical instruments supplier’s stock valued at $888,000 after acquiring an additional 1,242 shares during the period. Finally, Global Retirement Partners LLC grew its position in shares of Insulet by 560.2% in the fourth quarter. Global Retirement Partners LLC now owns 647 shares of the medical instruments supplier’s stock valued at $169,000 after purchasing an additional 549 shares during the last quarter.

Insider Transactions at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Insulet Price Performance

Shares of PODD stock opened at $282.80 on Monday. The stock’s fifty day simple moving average is $272.98 and its 200 day simple moving average is $247.87. Insulet Co. has a one year low of $160.19 and a one year high of $289.46. The firm has a market cap of $19.84 billion, a price-to-earnings ratio of 48.84, a P/E/G ratio of 3.62 and a beta of 1.23. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. On average, analysts expect that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on PODD shares. JPMorgan Chase & Co. raised their target price on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Raymond James restated an “outperform” rating and issued a $328.00 price objective (up previously from $294.00) on shares of Insulet in a research note on Friday. Canaccord Genuity Group upped their target price on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday. Citigroup raised their price target on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Morgan Stanley upped their price objective on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $289.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.